28 results about "Angiogenesis growth factor" patented technology

The present application relates to the technical field of wound repair, and provides a traditional Chinese medicine composition for promoting wound healing and a preparation method thereof.The traditional Chinese medicine composition comprises a first traditional Chinese medicine composition and a second traditional Chinese medicine composition which are applied to the acute phase and the repair proliferation phase.The former comprises naked flower purple perilla extract, nectarine leaf extract, purple perilla extract, dragon's blood micro powder, spironast extract, centella asiatica volatile oil, rhubarb extract, borneol, mussel mucin, medicinal glycerol and purified water.The latter comprises red algae extract, nectarine leaf extract, radix astragali extract, panax notoginseng total saponins, aloe extract, dendrobium officinale extract, sea buckthorn extract, pinctada martensii purified peptide, snail glycosaminoglycan, medicinal glycerol and purified water.The composition can play the roles of antibiosis, anti-inflammation, hemostasis, analgesia and astringency in the acute phase, and can promote angiogenesis, collagen synthesis and epithelial regeneration in the repair proliferation phase, so that the wound is rapidly repaired and healed.

The application relates to the application of lycorine hydrochloride in the preparation of a medicine for inhibiting the proliferation of a neointimal in a blood vessel. Lycorine hydrochloride has the effect of inhibiting the proliferation of a neointimal in a blood vessel, and the effect is mainly realized by inhibiting the proliferation and migration of vascular smooth muscle cells. In the body, the results show that lycorine hydrochloride can significantly inhibit the intimal proliferation caused by left common carotid artery ligation, and in vitro experiments prove that lycorine hydrochloride can intervene in the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB. Lycorine hydrochloride inhibits the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB, and the proliferation of a neointimal in a blood vessel through a MAPKs signal path. The application provides data for preparing lycorine hydrochloride into a medicine for inhibiting the proliferation of a neointimal in a blood vessel, and is expected to be applied to the prevention and treatment of complications after percutaneous coronary intervention, such as restenosis or in-stent thrombosis, and can become a potential medicine for intervening in restenosis.

This application relates to the fields of biomedicine and wound repair technology, and particularly to the application of platelet exosomes in the treatment of diabetic wound healing. This application discloses the use of platelet exosomes in the preparation of products having one or more of the following functions: 1) prevention and / or treatment of diabetic foot; 2) promotion of wound healing and / or tissue repair; 3) shortening wound healing time; 4) promoting granulation tissue growth; 5) enhancing wound angiogenesis; 6) alleviating inflammatory responses; 7) inhibiting the expression of pro-inflammatory factors; 8) promoting the expression of anti-inflammatory factors; 9) reducing MMP-9 expression; and 10) increasing MMP-2 expression. It is particularly suitable for the treatment of diabetic foot ulcers, delayed wound healing, and related complications, and also covers the use of this product in the preparation of diabetic foot treatment drugs and medical dressings.

This invention discloses an intestinal fungus Saccharomyces cerevisiae M7015 and its applications belong to the field of microbial technology. Saccharomyces cerevisiae The accession number for M7015 is GDMCC No. 66195. This invention first demonstrated, using a mouse subcutaneous stroma embolism model, that the aforementioned strain can promote angiogenesis; secondly, using mouse and Bama miniature pig myocardial infarction models, it was found that the aforementioned strain can promote collateral angiogenesis in ischemic areas of the heart and improve cardiac function. This invention not only fully elucidates... Saccharomyces cerevisiae M7015 promotes the formation of collateral vessels in the heart and improves cardiac function, and also reveals the broad application prospects of this bacterium in the treatment of vascular diseases.

The object of this invention is to provide novel pharmaceutical agents that can be used for various treatments. The pharmacological compositions of this invention are characterized by comprising extracellular vesicles derived from equine mesenchymal stem cells. The pharmacological compositions of this invention are tissue repair agents, anti-inflammatory agents, angiogenic agents, or wound healing agents.

The application discloses a kind of fibroblast growth factor 2 and mesenchymal cell co-loaded freeze-dried collagen support and its preparation method and application, belong to the technical field of biomedical materials, by adding sulfated polysaccharide to collagen solution, it is formed freeze-dried collagen support containing sulfated polysaccharide by vacuum freeze-drying, it is combined with fibroblast growth factor 2 incubation, obtain the freeze-dried collagen support of loading fibroblast growth factor 2, again mesenchymal cell is inoculated in the freeze-dried collagen support of loading fibroblast growth factor 2, and the freeze-dried collagen support of fibroblast growth factor 2 and mesenchymal cell co-loading is prepared.The support obtained by the application can efficiently combine fibroblast growth factor 2, support the adhesion growth of mesenchymal cell simultaneously, promote mesenchymal cell to migrate to the inside of support, realize the uniform distribution of cell in support, and can promote angiogenesis, provide new and efficient carrier for cell transplantation treatment.

The present application relates to the structure of a clero dene diterpene compound in fierce taste foot bone crisp, preparation method and its application in antitumor, the compound has the structure as shown in figure 1.The compound of the present application has tumor proliferation and metastasis inhibitory activity and angiogenesis inhibitory activity, and can be used for the development and application of antitumor drugs.

MicroRNA modified umbilical cord mesenchymal stem cells and exosomes and applications. The present application provides a treatment technology based on miR-210 mutant umbilical cord mesenchymal stem cells and exosomes. By specifically modifying the miR-210 sequence, a mutant with enhanced stability and targeting efficiency is obtained. After being introduced into umbilical cord mesenchymal stem cells, exosomes with high expression of the mutant can be prepared. The exosomes show significant therapeutic effect in various disease models, including promoting angiogenesis, accelerating wound repair and neuroprotection. The present application simultaneously protects the mutant sequence, recombinant vector, recombinant cell and its preparation method, and the application of the exosomes in the preparation of drugs for treating ischemic diseases and tissue damage. This technology optimizes the sequence and delivery system of miR-210, providing a new solution for tissue repair.

The application discloses application of harman alkaline in preparation of a medicine for treating and / or preventing myocardial infarction; the application firstly finds that the harman alkaline can be used for treating and / or preventing myocardial infarction. Meanwhile, the harman alkaline can significantly reduce a myocardial infarction area, improve heart function, and promote blood vessel neogenesis in an infarction edge area; and the harman alkaline can also up-regulate protein expression of CD31. In a cell experiment, the harman alkaline can promote HUVEC cell migration and proliferation after H2O2 injury. The application discloses the anti-myocardial infarction effect of the harman alkaline, provides a new medicine for myocardial infarction treatment, and has important clinical application value.

This invention provides the application of exercise-induced sweat extract from healthy individuals in the preparation of a topical medication for diabetic foot ulcers, belonging to the field of biomedicine. Addressing the problems of high cost and limited efficacy of existing treatments, this invention creatively proposes to collect, wash, centrifuge, and filter sweat from healthy individuals induced by specific moderate-intensity aerobic exercise to prepare a sterile extract, which can be used as an active ingredient for topical treatment of diabetic foot ulcers. This sweat extract is rich in various bioactive components. In vitro transcriptomic analysis shows that it can reverse the abnormal gene expression profile associated with diabetic foot ulcers. In vivo animal experiments have confirmed that its topical application can significantly accelerate the healing of diabetic wounds through multi-target synergistic effects of anti-inflammation, angiogenesis, epithelialization, and collagen deposition, with effects comparable to recombinant growth factors. This invention provides a novel treatment strategy that is natural, safe, low-cost, and highly effective, with broad clinical application prospects.

This invention discloses the application of induced pluripotent stem cell (EPC) derived from induced pluripotent stem cell differentiation in the preparation of stroke therapeutic agents. Through intravenous injection of EPCs into an animal model of stroke, this invention demonstrates that this method can treat stroke by inhibiting atherosclerosis, reducing cerebral infarction levels, promoting angiogenesis in lesioned brain tissue, improving inflammatory responses in lesioned brain tissue, and repairing nerve damage and brain injury. The above research results of this invention provide a new treatment method for stroke in clinical practice.

This invention discloses a traditional Chinese medicine shampoo for androgenetic alopecia caused by liver and kidney deficiency, its preparation method, and its application. Belonging to the field of traditional Chinese medicine technology, the shampoo uses processed Polygonum multiflorum, wine-processed Ligustrum lucidum, Eclipta prostrata, ginseng, Angelica sinensis, safflower, Salvia miltiorrhiza, Platycladus orientalis leaves, mulberry leaves, honey-processed mulberry bark, Sophora flavescens, Cnidium monnieri, Paeonia suffruticosa, Cercis chinensis bark, ginger, Sapindus mukorossi, Gleditsia sinensis, and Clematis chinensis as raw materials, prepared through water extraction and concentration. This invention achieves both symptomatic and root-cause treatment, addressing both the underlying cause and symptoms. It intervenes in androgenetic alopecia through the HIF-1 / VEGE and IL-17 pathways, promoting angiogenesis and improving microcirculation in the scalp, inhibiting follicular immune inflammation, and creating a favorable environment for hair follicle growth. Compared with existing technologies, this invention has irreplaceable advantages in improving local symptoms such as oily scalp, itching, and dandruff.

This invention discloses the application of gels and fibroblasts in the preparation of drugs for treating skin defects, belonging to the fields of biomedicine and tissue engineering technology. Early application provides a moist microenvironment to accelerate epithelial migration and achieve rapid wound closure; later, intradermal injection of fibroblasts promotes collagen remodeling and angiogenesis; ultimately achieving synergistic optimization of early rapid closure and later dermal regeneration.

The application relates to the field of biological medicine, and particularly relates to a cold storage solution and application of a combined traditional Chinese medicine compound biological stent drug delivery system in eardrum repair. The cold storage solution comprises a basic solution and L-alanyl-L-glutamine; the basic solution comprises a STEEN solution. The cold storage solution can promote metabolism and synthesis of glutathione of fat grafts, regulate ROS mitochondrial oxidative stress, reduce cold storage damage of the fat grafts, and improve the cold storage quality of the fat grafts. Meanwhile, the application uses Shengji Yuhong collagen sponge which contains an important classical prescription for promoting repair, forms a functional biological material with supporting and pro-angiogenic effects, forms a linkage mode of "double-stage regulation before and after transplantation", closely combines the actual difficulties of cell damage of fat groups and reduction of repair success rate caused by long eardrum repair time in the clinic, explores a brand-new research mode for improving the eardrum repair scheme, and has far-reaching clinical significance.

The application belongs to the technical field of biomedicine, and particularly relates to application of circRNA_0004468 in a drug for treating ischemic stroke. The application first discloses and verifies a competitive endogenous RNA (ceRNA) regulatory axis composed of circRNA_0004468, miR-1224 and VEGFA, which is a key molecular mechanism for RIPostC to play a neuroprotective role. Experiments prove that circRNA_0004468 can adsorb miR-1224 as a "molecular sponge", thereby relieving the inhibition of miR-1224 on VEGFA, up-regulating the expression of VEGFA, and then activating the PI3K / AKT signaling pathway and promoting angiogenesis, so as to finally reduce ischemia / reperfusion injury at the cell (OGD / R model) and animal (tMCAO model) levels.

This invention belongs to the field of nanobiomedicine technology, specifically relating to a mitochondrial-targeting copper-based nanoparticle (Qu@Cu-SS31) and its application in the preparation of drugs for treating myocardial infarction. The nanoparticles consist of quercetin (Que) and copper ions (Cu²⁺). + The nanoparticles, consisting of a self-assembly of the mitochondrial-targeting peptide SS31, exhibit a uniform, near-spherical morphology with an average particle size of 17.2 ± 1.6 nm. These nanoparticles specifically target cardiomyocyte mitochondria, responsively releasing Cu²⁺. + Furthermore, Qu@Cu-SS31 restores cardiomyocyte copper homeostasis by downregulating the copper metabolism negative regulator COMMD1, the copper uptake protein CTR1, and the copper chaperone protein CCS. Based on this, Qu@Cu-SS31 exhibits remarkable SOD-like and CAT-like enzyme activities, efficiently scavenging various reactive oxygen species / reactive nitrogen species and significantly reducing oxidative stress. Simultaneously, it inhibits NLRP3 inflammasome activation and Caspase-1-mediated pyroptosis, regulates the Bcl-2 / Bax balance to inhibit apoptosis, and promotes vascular endothelial growth factor expression and angiogenesis.

This invention belongs to the field of biomedical technology, specifically disclosing an injectable embolic agent, its preparation method, and its application. The embolic agent is a hydrocolloid system containing core-shell structured nanoparticles: the core contains Cu... 2+ Salt and ATOX1 inhibitors, where ATOX1 inhibitors can inhibit copper ion efflux and promote intracellular copper accumulation, and interact with Cu 2+ It synergistically induces copper death in tumor cells; the shell is a thermosensitive block copolymer hydrogel that can interact with Cu. 2+ Coordination bonds are formed, enhancing the stability of nanoparticles, while a sol-gel transition occurs at physiological temperatures, enabling precise vascular embolization; the overall core-shell structure allows for the formation of Cu... 2+ The sustained-release effect of ATOX1 inhibitors was observed. In the VX2 rabbit hepatocellular carcinoma model, this embolization agent significantly improved tumor necrosis rate and reduced metastasis rate compared to traditional iodized oil embolization; it also downregulated hypoxia- and angiogenesis-related factors such as HIF-1α, VEGF, and CD31, inhibited MMP9-mediated tumor invasion and metastasis, and promoted CD8+. + T-cell infiltration effectively improves the tumor immunosuppressive microenvironment after transarterial chemoembolization.

This invention discloses the application of cell membrane-modified engineered hypoxic stem cell exosomes in the preparation of drugs for treating myocardial infarction. Mesenchymal stem cells are pretreated with hypoxia, and the conditioned medium for these cells is collected. Exosomes are then collected by differential centrifugation, and cell membranes are coated onto the surface of the exosomes to obtain hybrid nanovesicles, i.e., cell membrane-modified engineered hypoxic stem cell exosomes. This invention overcomes the lack of targeting in MSC-Exo therapy and solves the problem that current exosome angiogenesis-promoting functions need further enhancement and that poor targeting leads to unsatisfactory therapeutic effects in myocardial infarction.

This application provides a CA-crosslinked, Isatis indigotica-derived carbon dots-loaded dual-responsive OPU hydrogel, its preparation method, and its applications. The hydrogel is prepared using oxidized pullulan as a backbone and chlorogenic acid as a crosslinking agent; carbon dots derived from Isatis indigotica are loaded into the hydrogel. This hydrogel exhibits excellent injectability and self-healing ability, effectively conforming to irregular wound surfaces. Under the stimulation of the acidic and oxidative microenvironment unique to infected wounds, the hydrogel gradually dissociates, achieving controlled release of Isatis indigotica carbon dots and chlorogenic acid. The Isatis indigotica carbon dots exhibit potent antibacterial activity, while chlorogenic acid synergistically works to efficiently scavenge excess reactive oxygen species and reactive nitrogen species, promoting tissue regeneration and reducing inflammatory responses. In vitro and in vivo experiments have confirmed that this hydrogel possesses excellent biocompatibility, exerting anti-infective, antioxidant, and anti-inflammatory effects in the early stages of healing, and promoting angiogenesis and accelerating wound healing in the later stages.

The application belongs to the field of biological medicine, and provides application of TGF-beta / Smad signal pathway in treatment of corneal neovascularization after corneal alkali burn. The application proves that by inhibiting the TGF-beta / Smad signal pathway, the alkali burn-induced corneal neovascularization can be significantly reduced, and the corneal pathological damage is improved, and the mechanism of action involves regulating M2 type macrophage polarization and inhibiting the process of cellular ferroptosis of corneal tissue. It is found that by using a specific inhibitor SB-431542, the expression of TGF-beta1 and p-Smad2 / 3 proteins can be effectively reduced, the angiogenic factors such as VEGFA and CD31 are reduced, the inflammatory factors such as IL-4 and IL-10 are down-regulated, the GSH level is restored, and the Fe 2+ and MDA contents are reduced. The application is suitable for developing a targeted therapeutic drug for pathological neovascularization after corneal alkali burn, and provides a theoretical basis.

The embodiment of the application discloses a composite material containing umbilical cord mesenchymal stromal cell exosome combined with ECM and a preparation method and application thereof, and belongs to the technical field of biological medicine. The composite material comprises the following raw materials in parts by weight: 15-25 parts of umbilical cord mesenchymal stromal cell exosome, 50-75 parts of ECM, and 10-20 parts of stabilizer. The composite material provided by the application has excellent wound repair activity, can significantly promote the transformation of a chronic wound from an inflammation period to a proliferation period, accelerate the processes of angiogenesis, granulation tissue formation and epithelialization, and can be applied to the repair of chronic skin wounds such as diabetic foot ulcers, venous ulcers and pressure injuries.

The application relates to the technical field of medical devices, and discloses an absorbable door opening maintainer for cervical vertebra canal plasty, wherein the maintainer body is integrally formed by using high-strength absorbable material, a hollow bone ingrowth matrix is arranged in the maintainer body in the axial direction, the maintainer body comprises a spiral coupler structure and a zero-cut trace cable structure, and the spiral coupler structure and the zero-cut trace cable structure are both hollow structures. In the application, the whole maintainer is made of high-strength absorbable material, is matched with absorbable sutures of the same type, the degradation periods of the two are mutually adapted, the degradation process is synchronized with the bone growth period, secondary surgery for removal is not needed, secondary damage to bone and soft tissues is avoided, the multi-dimensional bone ingrowth channel is beneficial to the migration, proliferation and angiogenesis of bone cells, biological fusion between the maintainer and the host bone is promoted, and the bone repair process is accelerated.

This invention discloses a heparin trisaccharide compound, its preparation method, and its applications, belonging to the field of compound preparation technology. The heparin trisaccharide compound is mainly prepared by the following method: linking a monosaccharide donor and a disaccharide acceptor through glycosylation, then reacting in a methanol / sodium methoxide system or a tetrahydrofuran / sodium hydroxide / water system, followed by sequential O-sulfonation, catalytic hydrogenation, and N-sulfonation post-treatment steps to obtain the heparin trisaccharide compound. This compound has a well-defined structure, a single component, and exhibits anti-angiogenic activity and anti-tumor potential.

The application discloses a collagen-exosome composite film material for uterine cavity repair and a preparation method and application thereof. The collagen-exosome composite film material is prepared by compounding type I collagen and mesenchymal stem cell-derived exosomes. The type I collagen is obtained by cross-linking reaction of animal tissue and a cross-linking agent. The mesenchymal stem cell-derived exosomes express one or more exosome marker proteins of CD9, CD63 and TSG101. The collagen-exosome composite film material disclosed by the application maintains flexibility at body temperature, can be attached to an endometrial wound surface, realizes slow release of the exosomes and uterine cavity physical isolation, has good biological activity, and can promote endometrial regeneration and angiogenesis.

This invention discloses a novel small molecule compound, ZYZ329, which exerts anti-tumor effects dependent on gut microbiota, reshapes the gut microbiota, and increases ILA levels. It can target and inhibit SMYD, and has potential applications in the treatment of non-small cell lung cancer and angiogenesis-related diseases. Furthermore, it can inhibit the proliferation, migration, and tubule formation of human umbilical vein endothelial cells, making it a promising new drug with multiple clinical applications.